我国单倍体造血干细胞移植的现状和未来  

The present and future of haploidentical hematopoietic stem cell transplantation in China

作　　者：莫晓冬[1] 黄晓军[1] Mo Xiaodong;Huang Xiaojun(Peking University People's Hospital&Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Bejing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China)

机构地区：[1]北京大学人民医院,北京大学血液病研究所,国家血液系统疾病临床医学研究中心,造血干细胞移植治疗血液病北京市重点实验室,北京100044

出　　处：《中华血液学杂志》2024年第7期625-628,共4页Chinese Journal of Hematology

基　　金：国家重点研发计划(2022YFA1103300、2022YFC2502606);国家自然科学基金面上项目(82170208)。

摘　　要：供者缺乏是造血干细胞移植广泛使用的最大障碍。新型移植方案的建立、完善使得单倍体造血干细胞移植成为临床常规, 大量血液病患者得以从中获益, 单倍体供者已经成为中国异基因造血干细胞移植最重要的供者来源。本文聚焦单倍体造血干细胞移植在我国开展的现状及未来发展趋势, 增加临床医师对单倍体造血干细胞移植的了解。The lack of donors is the biggest obstacle to the widespread use of hematopoietic stem cell transplantation.The establishment and improvement of new transplantation schemes have made haploid hematopoietic stem cell transplantation a clinical routine,benefiting a large number of patients with hematological diseases.Haploid donors have become the most important source of donors for allogeneic hematopoietic stem cell transplantation in China.This article focuses on the current situation and future development trends of haploid hematopoietic stem cell transplantation in China,in order to increase the understanding of clinical doctors on haploid hematopoietic stem cell transplantation.

关 键 词：血液病患者 造血干细胞移植 临床医师 现状和未来 单倍体 移植方案 供者来源 现状及未来 

分 类 号：R457.7[医药卫生—治疗学]